A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia (Q44041367)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 July 2017

Language	Label	Description	Also known as
English	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia	scientific article published on 18 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia (English)

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

Nicholas J. Short

1

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

14 June 2018

15

object named as

Zeev Estrov

1 reference

Europe PubMed Central

14 June 2018

William G Wierda

17

object named as

William G Wierda

1 reference

Europe PubMed Central

14 June 2018

Gautam Borthakur

12

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

14 June 2018

3

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

14 June 2018

22

object named as

Elias Jabbour

1 reference

Europe PubMed Central

14 June 2018

Guillermo Garcia-Manero

6

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

14 June 2018

Marina Konopleva

14

object named as

Marina Konopleva

1 reference

Europe PubMed Central

14 June 2018

Jorge Eduardo Cortes

21

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

14 June 2018

William Plunkett

7

object named as

William Plunkett

1 reference

Europe PubMed Central

14 June 2018

Naveen Pemmaraju

10

object named as

Naveen Pemmaraju

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

16

object named as

Tapan M Kadia

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Courtney D DiNardo

18

object named as

Courtney D DiNardo

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

9

object named as

Koji Sasaki

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

11

object named as

Naval G Daver

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

19

object named as

Mark Brandt

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

4

object named as

Xuelin Huang

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

5

object named as

Lianchun Xiao

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Susan M O'Brien

20

object named as

Susan M O'Brien

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

author name string

Varsha Gandhi

8

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Nitin Jain

13

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

publication date

18 July 2017

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Leukemia & Lymphoma

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

59

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

813-820

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

4

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

The role of clofarabine in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Purine nucleoside analogues in the treatment of myleoid leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Biochemical modulation of arabinosylcytosine for therapy of leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

14 June 2018

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

16 June 2018

How I treat refractory and early relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

16 June 2018

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

16 June 2018

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773400

15 August 2018

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28718728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/10428194.2017.1349907

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

1 reference

Europe PubMed Central

14 June 2018

http://europepmc.org/abstract/PMC/5773400

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44041367&oldid=2117034556"